HALOZYME THERAPEUTICS, INC.HALO财报
Nasdaq · 医疗保健 · 生物制品（不含诊断物质）
Halozyme Therapeutics是一家美国生物技术企业，专注于肿瘤领域创新疗法研发，核心管线均针对肿瘤微环境进行靶向干预，致力于为全球癌症患者提供更安全高效的治疗选择。
营收
$354.3M
毛利润
$299.0M
营业利润
$217.9M
净利润
$175.2M
毛利率
84.4%
营业利润率
61.5%
净利率
49.5%
同比增长
22.1%
EPS
$1.43
资金流向
HALOZYME THERAPEUTICS, INC. Q3 2025 财务摘要
HALOZYME THERAPEUTICS, INC. Q3 2025营收 $354.3M（同比增长 22.1%），净利润 $175.2M（同比增长 27.9%）（净利率 49.5%）。销售成本 $55.2M，运营费用 $81.1M。
核心财务指标
| 总营收 | $354.3M |
|---|---|
| 净利润 | $175.2M |
| 毛利率 | 84.4% |
| 营业利润率 | 61.5% |
| 报告期 | Q3 2025 |
营收拆解
HALOZYME THERAPEUTICS, INC. Q3 2025营收 $354.3M 共来自 6 个业务板块，最大板块 Royalty 贡献 $236.0M（占 66.6%）。
| 业务分部 | 营收 | 占比 |
|---|---|---|
| Royalty | $236.0M | 66.6% |
| Proprietary Products Sales | $52.2M | 14.7% |
| Bulkr Hu PH20 | $32.5M | 9.2% |
| Sales Based Milestone | $20.0M | 5.6% |
| Device Partnered Products | $9.5M | 2.7% |
| Device Licensing And Development | $4.0M | 1.1% |
HALOZYME THERAPEUTICS, INC. 分部营收 — 季度趋势
HALOZYME THERAPEUTICS, INC. 过去 4 个季度各业务板块营收走势，展示 Royalty and Proprietary Products Sales 等业务的变化。
| 业务分部 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Royalty | $258.0M | $236.0M | $205.6M | $168.2M |
| Proprietary Products Sales | $59.6M | $52.2M | $46.5M | $36.3M |
| Bulkr Hu PH20 | — | $32.5M | $23.3M | $27.0M |
| Sales Based Milestone | — | $20.0M | $10.0M | — |
| Device Partnered Products | $12.9M | $9.5M | $11.8M | $14.7M |
HALOZYME THERAPEUTICS, INC. 年度营收
HALOZYME THERAPEUTICS, INC. 历年营收汇总，含各年度总量（例如 2025 年营收为 $1.4B）。
| 年份 | 年营收 |
|---|---|
| 2025 | $1.4B |
| 2024 | $1.0B |
| 2023 | $829.3M |
| 2022 | $660.1M |
HALOZYME THERAPEUTICS, INC. 季度营收与净利润历史
HALOZYME THERAPEUTICS, INC. 最近 8 个季度的营收、净利润及同比增速
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 2025 | $451.8M | +51.6% | $-141.6M | -31.3% |
| Q3 2025 | $354.3M | +22.1% | $175.2M | 49.5% |
| Q2 2025 | $325.7M | +40.8% | $165.2M | 50.7% |
| Q1 2025 | $264.9M | +35.2% | $118.1M | 44.6% |
| Q4 2024 | $298.0M | +29.5% | $137.0M | 46.0% |
| Q3 2024 | $290.1M | +34.3% | $137.0M | 47.2% |
| Q2 2024 | $231.4M | +4.7% | $93.2M | 40.3% |
| Q1 2024 | $195.9M | +20.8% | $76.8M | 39.2% |
利润表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 营收 | $195.9M | $231.4M | $290.1M | $298.0M | $264.9M | $325.7M | $354.3M | $451.8M |
| 同比增长 | 20.8% | 4.7% | 34.3% | 29.5% | 35.2% | 40.8% | 22.1% | 51.6% |
资产负债表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 总资产 | $1.84B | $1.97B | $2.12B | $2.06B | $2.20B | $2.05B | $2.22B | $2.53B |
| 总负债 | $1.66B | $1.68B | $1.67B | $1.70B | $1.71B | $1.72B | $1.72B | $2.48B |
| 股东权益 | $177.8M | $289.4M | $452.7M | $363.8M | $482.3M | $332.7M | $503.9M | $48.8M |
现金流量表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 经营性现金流 | $129.4M | $55.8M | $115.4M | $178.5M | $154.2M | $99.7M | $178.6M | $219.0M |